Addex Therapeutics Ltd (ADXN) Financial Ratios
19 years of historical data (2006–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.46
↓-79% vs avg
5yr avg: 2.20
30Y Low0.6·High4.1
ROE
↑
130.4%
↓+214% vs avg
5yr avg: -114.0%
30Y Low-420%·High130%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ADXN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Addex Therapeutics Ltd trades at 0.7x earnings, 22% below its 5-year average of 0.8x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 97%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $6M | $4M | $5M | $36M | $60M | — | — | — | — | — |
| Enterprise Value | $399435 | $2M | $225197 | $-1839547 | $16M | $41M | — | — | — | — | — |
| P/E Ratio → | 0.65 | 0.83 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.94 | 14.16 | 2.32 | 3.34 | 12.27 | 16.49 | — | — | — | — | — |
| P/B Ratio | 0.46 | 0.59 | 3.27 | 0.97 | 2.11 | 4.08 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ADXN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.00 | 0.14 | -1.29 | 5.41 | 11.48 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ADXN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Addex Therapeutics Ltd earns an operating margin of -681.8%. Operating margins have expanded from -741.0% to -681.8% over the past 3 years, signaling improving operational efficiency. Return on equity of 130.4% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 91.7% | 97.6% | 94.0% | — | — |
| Operating Margin | -681.8% | -681.8% | -139.1% | -741.0% | -531.7% | -338.9% | -528.6% | -23.6% | -647.1% | -18059.9% | -9597.6% |
| Net Profit Margin | 1746.0% | 1746.0% | -654.5% | -1462.6% | -526.4% | -355.9% | -535.0% | -27.2% | -656.2% | -18174.1% | -10432.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 130.4% | 130.4% | -348.5% | -190.5% | -97.3% | -64.1% | -45.6% | -8.1% | -420.3% | -334.5% | -209.7% |
| ROA | 92.1% | 92.1% | -163.4% | -135.0% | -71.9% | -48.3% | -39.3% | -7.3% | -138.2% | -137.7% | -122.1% |
| ROIC | -103.3% | -103.3% | — | — | — | — | — | — | — | — | — |
| ROCE | -47.4% | -47.4% | -66.5% | -90.1% | -88.7% | -55.8% | -43.4% | -6.9% | -320.4% | -273.0% | -177.8% |
ADXN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $41994, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.30 | 0.08 | 0.03 | 0.04 | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | -3.07 | -1.34 | -1.18 | -1.24 | -1.21 | -1.06 | -1.93 | -6.48 | -1.58 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -23.91 | — | — | — |
| Interest Coverage | -1383.08 | -1383.08 | -115.53 | -220.38 | -242.63 | -184.01 | -114.01 | -6.86 | -71.34 | -453.85 | -25.62 |
Net cash position: cash ($3M) exceeds total debt ($41994)
ADXN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Addex Therapeutics Ltd's current ratio of 4.42x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.39x to 4.42x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.42 | 4.42 | 1.46 | 2.39 | 5.31 | 5.38 | 5.70 | 18.06 | 2.07 | 1.33 | 2.70 |
| Quick Ratio | 4.42 | 4.42 | 1.46 | 2.39 | 5.31 | 5.34 | 5.70 | 18.06 | 2.07 | 1.33 | 2.70 |
| Cash Ratio | 4.17 | 4.17 | 1.34 | 2.12 | 4.96 | 5.18 | 5.55 | 17.86 | 1.75 | 1.13 | 2.56 |
| Asset Turnover | — | 0.04 | 0.35 | 0.17 | 0.13 | 0.18 | 0.08 | 0.14 | 0.16 | 0.01 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 14.01 | 34.23 | 153.53 | 40.60 | 6.91 | 15.59 | 16.49 | 221.88 | 4649.08 | 1196.18 |
ADXN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Addex Therapeutics Ltd does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 100.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 120.0% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $817606 | $619230 | $376540 | $284330 | $222348 | $220235 | $194110 | $107845 | $95102 | $90433 |
Peer Comparison
Compare ADXN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ADXNYou | $5M | 0.7 | — | — | 100.0% | -681.8% | 130.4% | -103.3% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 NBIX | $15B | 32.0 | 22.7 | 20.1 | 98.2% | 21.6% | 16.4% | 16.1% | 0.6 |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 ANIK | $203M | -19.9 | — | 46.5 | 56.6% | -9.8% | -7.3% | -7.1% | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 19 years · Updated daily
See ADXN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADXN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADXN vs ACAD
Side-by-side business, growth, and profitability comparison vs ACADIA Pharmaceuticals Inc..
Start ComparisonADXN — Frequently Asked Questions
Quick answers to the most common questions about buying ADXN stock.
What is Addex Therapeutics Ltd's P/E ratio?
Addex Therapeutics Ltd's current P/E ratio is 0.7x. The historical average is 0.8x.
What is Addex Therapeutics Ltd's ROE?
Addex Therapeutics Ltd's return on equity (ROE) is 130.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -114.1%.
Is ADXN stock overvalued?
Based on historical data, Addex Therapeutics Ltd is trading at a P/E of 0.7x. Compare with industry peers and growth rates for a complete picture.
What are Addex Therapeutics Ltd's profit margins?
Addex Therapeutics Ltd has 100.0% gross margin and -681.8% operating margin.